Skip to main content
Top
Published in: Current Treatment Options in Neurology 8/2016

01-08-2016 | Neurologic Manifestations of Systemic Disease (N Scolding and C Rice, Section Editors)

Management of Neurologic Manifestations in Patients with Liver Disease

Authors: José M. Ferro, MD, PhD, Pedro Viana, MD, Patrícia Santos, MD

Published in: Current Treatment Options in Neurology | Issue 8/2016

Login to get access

Opinion statement

Liver disease, both in its acute and chronic forms, can be associated with a wide spectrum of neurologic manifestations, both central and peripheral, ranging in severity from subclinical changes to neurocritical conditions. Neurologists are frequently consulted to participate in their management. In this review, we present an overview of management strategies for patients with hepatic disease whose clinical course is complicated by neurologic manifestations. Type A hepatic encephalopathy (HE), which occurs in acute liver failure, is a neurologic emergency, and multiple measures should be taken to prevent and treat cerebral edema. In Type C HE, which occurs in chronic liver disease, management should be aimed at correcting precipitant factors and hyperammonemia. There is an increasing spectrum of drug treatments available to minimize ammonia toxicity. Acquired hepatocerebral degeneration is a rare complication of the chronic form of HE, with typical clinical and brain MRI findings, whose most effective treatment is liver transplantation. Epilepsy is frequent and of multifactorial cause in patients with hepatic disease, and careful considerations should be made regarding choice of the appropriate anti-epileptic drugs. Several mechanisms increase the risk of stroke in hepatic disease, but many of the drugs used to treat and prevent stroke are contraindicated in severe hepatic failure. Hepatitis C infection increases the risk of ischemic stroke. Hemorrhagic stroke is more frequent in patients with liver disease of alcoholic etiology. Viral hepatitis is associated with a wide range of immune-mediated complications, mostly in the peripheral nervous system, which respond to different types of immunomodulatory treatment. Several drugs used to treat hepatic disease, such as the classical and the new direct-acting antivirals, may have neurologic complications which in some cases preclude its continued use.
Literature
1.
go back to reference Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.CrossRefPubMed Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.CrossRefPubMed
2.
go back to reference Ferro JM, Oliveira S. Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep. 2014;14:487.CrossRefPubMed Ferro JM, Oliveira S. Neurologic manifestations of gastrointestinal and liver diseases. Curr Neurol Neurosci Rep. 2014;14:487.CrossRefPubMed
3.
go back to reference Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83–100.CrossRefPubMed Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83–100.CrossRefPubMed
4.
go back to reference Palomero-Gallagher N, Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys. 2013;536:109–21.CrossRefPubMed Palomero-Gallagher N, Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys. 2013;536:109–21.CrossRefPubMed
5.••
go back to reference Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–35. The most recently published guidelines with substantial discussion and levels of evidence of different treatment options for hepatic encephalopathy in chronic liver disease.CrossRefPubMed Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–35. The most recently published guidelines with substantial discussion and levels of evidence of different treatment options for hepatic encephalopathy in chronic liver disease.CrossRefPubMed
6.•
go back to reference Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34. Clear and concise review on the management of acute liver failure.CrossRefPubMed Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34. Clear and concise review on the management of acute liver failure.CrossRefPubMed
7.••
go back to reference Polson J, Lee WM. AASLD position paper: the management of acute liver failure: update 2011. Hepatology. 2005;41:1179–97. Most recent practice recommendations for the management of acute liver failure, by the American Association for The Study of Liver Disease.CrossRefPubMed Polson J, Lee WM. AASLD position paper: the management of acute liver failure: update 2011. Hepatology. 2005;41:1179–97. Most recent practice recommendations for the management of acute liver failure, by the American Association for The Study of Liver Disease.CrossRefPubMed
8.
go back to reference Datar S, Wijdicks EFM. Neurologic manifestations of acute liver failure. Handb Clin Neurol. 2014;120:645–59.CrossRefPubMed Datar S, Wijdicks EFM. Neurologic manifestations of acute liver failure. Handb Clin Neurol. 2014;120:645–59.CrossRefPubMed
9.•
go back to reference Sureka B, Bansal K, Patidar Y, Rajesh S, Mukund A, et al. Neurologic manifestations of chronic liver disease and liver cirrhosis. Curr Probl Diagn Radiol. 2015;44:449–61. Comprehensive review of the neuroimaging abnormalities related to chronic liver disease patients.CrossRefPubMed Sureka B, Bansal K, Patidar Y, Rajesh S, Mukund A, et al. Neurologic manifestations of chronic liver disease and liver cirrhosis. Curr Probl Diagn Radiol. 2015;44:449–61. Comprehensive review of the neuroimaging abnormalities related to chronic liver disease patients.CrossRefPubMed
10.
go back to reference Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42:1157–67.CrossRefPubMedPubMedCentral Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42:1157–67.CrossRefPubMedPubMedCentral
11.
go back to reference Vaquero J. Therapeutic hypothermia in the management of acute liver failure. Neurochem Int. 2012;60:723–35.CrossRefPubMed Vaquero J. Therapeutic hypothermia in the management of acute liver failure. Neurochem Int. 2012;60:723–35.CrossRefPubMed
12.
go back to reference Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure—a controlled clinical trial. J Hepatol. 2004;41:89–96.CrossRefPubMed Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure—a controlled clinical trial. J Hepatol. 2004;41:89–96.CrossRefPubMed
13.
go back to reference Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001;96:515–8.CrossRefPubMed Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol. 2001;96:515–8.CrossRefPubMed
14.
go back to reference Yamamoto Y, Nishiyama Y, Katsura K-I, Yamazaki M, Katayama Y. Hepatic encephalopathy with reversible focal neurologic signs resembling acute stroke: case report. J Stroke Cerebrovasc Dis. 2011;20:377–80.CrossRefPubMed Yamamoto Y, Nishiyama Y, Katsura K-I, Yamazaki M, Katayama Y. Hepatic encephalopathy with reversible focal neurologic signs resembling acute stroke: case report. J Stroke Cerebrovasc Dis. 2011;20:377–80.CrossRefPubMed
15.
go back to reference Ben Amor S, Saied MZ, Harzallah MS, Benammou S. Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature. Eur Spine J. 2014;23 Suppl 2:167–71.CrossRefPubMed Ben Amor S, Saied MZ, Harzallah MS, Benammou S. Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature. Eur Spine J. 2014;23 Suppl 2:167–71.CrossRefPubMed
16.
go back to reference Kori P, Sahu R, Jaiswal A, Shukla R. Hepatic myelopathy: an unusual neurological complication of chronic liver disease presenting as quadriparesis. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-009078 Kori P, Sahu R, Jaiswal A, Shukla R. Hepatic myelopathy: an unusual neurological complication of chronic liver disease presenting as quadriparesis. BMJ Case Rep. 2013. doi:10.​1136/​bcr-2013-009078
17.
go back to reference Premkumar M, Bagchi A, Kapoor N, Gupta A, Maurya G, et al. Hepatic myelopathy in a patient with decompensated alcoholic cirrhosis and portal colopathy. Case Reports Hepatol. 2012;2012:735906.CrossRefPubMedPubMedCentral Premkumar M, Bagchi A, Kapoor N, Gupta A, Maurya G, et al. Hepatic myelopathy in a patient with decompensated alcoholic cirrhosis and portal colopathy. Case Reports Hepatol. 2012;2012:735906.CrossRefPubMedPubMedCentral
18.
go back to reference Cui M, Zhang X, Mu F. Hepatic myelopathy associated with advanced liver cirrhosis. Saudi Med J. 2012;33:1352–4.PubMed Cui M, Zhang X, Mu F. Hepatic myelopathy associated with advanced liver cirrhosis. Saudi Med J. 2012;33:1352–4.PubMed
19.
go back to reference Baccarani U, Zola E, Adani GL, Cavalletti M, Schiff S, et al. Reversal of hepatic myelopathy after liver transplantation: fifteen plus one. Liver Transpl. 2010;16:1336–7.CrossRefPubMed Baccarani U, Zola E, Adani GL, Cavalletti M, Schiff S, et al. Reversal of hepatic myelopathy after liver transplantation: fifteen plus one. Liver Transpl. 2010;16:1336–7.CrossRefPubMed
20.•
go back to reference Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:789–96. Practice recommendations for the neurophysiological investigation of hepatic encephalopathy related to chronic liver disease.CrossRefPubMed Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:789–96. Practice recommendations for the neurophysiological investigation of hepatic encephalopathy related to chronic liver disease.CrossRefPubMed
21.
go back to reference Conn HO, Levy LL. The nonspecificity of electroencephalographic triphasic waves: the emperor defrocked. Hepatology. 1989;9:337–8.CrossRefPubMed Conn HO, Levy LL. The nonspecificity of electroencephalographic triphasic waves: the emperor defrocked. Hepatology. 1989;9:337–8.CrossRefPubMed
22.
go back to reference Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011;26:135–9.CrossRefPubMed Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011;26:135–9.CrossRefPubMed
23.•
go back to reference Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:629–35. Practice guidelines with extensive overview of neuropsychological tests used in hepatic encephalopathy related to chronic liver disease.CrossRefPubMed Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:629–35. Practice guidelines with extensive overview of neuropsychological tests used in hepatic encephalopathy related to chronic liver disease.CrossRefPubMed
24.
go back to reference Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res. 2014;44:E92–9.CrossRefPubMed Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res. 2014;44:E92–9.CrossRefPubMed
25.
26.
go back to reference Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci. 1993;38:916–22.CrossRefPubMed Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci. 1993;38:916–22.CrossRefPubMed
27.
go back to reference Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350—electrolyte solution for treatment of overt hepatic encephalopathy. JAMA Intern Med. 2014;174:1727.CrossRefPubMed Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350—electrolyte solution for treatment of overt hepatic encephalopathy. JAMA Intern Med. 2014;174:1727.CrossRefPubMed
28.
go back to reference Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767–77.CrossRefPubMedPubMedCentral Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767–77.CrossRefPubMedPubMedCentral
29.
go back to reference Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40:123–32.CrossRefPubMed Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40:123–32.CrossRefPubMed
30.
go back to reference Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.CrossRefPubMed Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.CrossRefPubMed
31.
go back to reference Zhu G-Q, Shi K-Q, Huang S, Wang L-R, Lin Y-Q, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther. 2015;41:624–35.CrossRefPubMed Zhu G-Q, Shi K-Q, Huang S, Wang L-R, Lin Y-Q, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther. 2015;41:624–35.CrossRefPubMed
32.
go back to reference Gluud L, Dam G, Borre M, Les I. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143(8):1263–8. Gluud L, Dam G, Borre M, Les I. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143(8):1263–8.
33.
go back to reference Bai M, Yang Z, Qi X, Fan D, Han G. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28:783–92.CrossRefPubMed Bai M, Yang Z, Qi X, Fan D, Han G. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28:783–92.CrossRefPubMed
34.
go back to reference Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak. 2011;21:666–71.PubMed Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak. 2011;21:666–71.PubMed
35.
go back to reference Sharma K, Pant S, Misra S, Dwivedi M, Misra A, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014;20:225–32.CrossRefPubMedPubMedCentral Sharma K, Pant S, Misra S, Dwivedi M, Misra A, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014;20:225–32.CrossRefPubMedPubMedCentral
36.
go back to reference Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res. 2012;42:1008–15.CrossRefPubMed Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res. 2012;42:1008–15.CrossRefPubMed
37.
go back to reference Jiang Q, Jiang G, Shi K, Cai H, Wang Y, et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013;12:803–9.PubMed Jiang Q, Jiang G, Shi K, Cai H, Wang Y, et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013;12:803–9.PubMed
38.
go back to reference Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis. 2011;26:281–9.CrossRefPubMed Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis. 2011;26:281–9.CrossRefPubMed
39.
go back to reference Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, et al. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013;25:352–8.CrossRefPubMed Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, et al. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013;25:352–8.CrossRefPubMed
40.
go back to reference Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gomez S, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184–92.CrossRefPubMed Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gomez S, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013;59:1184–92.CrossRefPubMed
41.
go back to reference Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RSJ, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–83.CrossRefPubMedPubMedCentral Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RSJ, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–83.CrossRefPubMedPubMedCentral
42.
go back to reference Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, et al. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int. 2012;32:410–9.PubMed Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, et al. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int. 2012;32:410–9.PubMed
43.
go back to reference Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014;2:CD003047.PubMed Junker AE, Als-Nielsen B, Gluud C, Gluud LL. Dopamine agents for hepatic encephalopathy. Cochrane Database Syst Rev. 2014;2:CD003047.PubMed
44.
go back to reference Ampuero J, Ranchal I, Nunez D, Diaz-Herrero M del M, Maraver M, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One. 2012;7:e49279.CrossRefPubMedPubMedCentral Ampuero J, Ranchal I, Nunez D, Diaz-Herrero M del M, Maraver M, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One. 2012;7:e49279.CrossRefPubMedPubMedCentral
45.
go back to reference Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448–52.CrossRefPubMed Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448–52.CrossRefPubMed
46.•
go back to reference Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36. Guidelines for nutritional management of hepatic encephalopathy in cirrhosis patients.CrossRefPubMed Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36. Guidelines for nutritional management of hepatic encephalopathy in cirrhosis patients.CrossRefPubMed
47.
go back to reference An J, Kim KW, Han S, Lee J, Lim Y-S. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418–26.CrossRefPubMed An J, Kim KW, Han S, Lee J, Lim Y-S. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418–26.CrossRefPubMed
48.
go back to reference García-Martínez R, Rovira A, Alonso J, Jacas C, Simón-Talero M, et al. hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplant. 2011;17:38–46.CrossRef García-Martínez R, Rovira A, Alonso J, Jacas C, Simón-Talero M, et al. hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplant. 2011;17:38–46.CrossRef
49.
go back to reference Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332–40.CrossRefPubMedPubMedCentral Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332–40.CrossRefPubMedPubMedCentral
50.
go back to reference Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60:521–8.CrossRefPubMed Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60:521–8.CrossRefPubMed
51.
go back to reference Tryc AB, Goldbecker A, Berding G, Rumke S, Afshar K, et al. Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. J Hepatol. 2013;58:698–705.CrossRefPubMed Tryc AB, Goldbecker A, Berding G, Rumke S, Afshar K, et al. Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. J Hepatol. 2013;58:698–705.CrossRefPubMed
52.
go back to reference Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013;28:261–7.CrossRefPubMed Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013;28:261–7.CrossRefPubMed
53.••
go back to reference Meissner W, Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol. 2011;100:193–7. Review of the most frequent clinical findings and treatment options for acquired hepatocerebral degeneration.CrossRefPubMed Meissner W, Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol. 2011;100:193–7. Review of the most frequent clinical findings and treatment options for acquired hepatocerebral degeneration.CrossRefPubMed
54.
go back to reference Maffeo E, Montuschi A, Stura G, Giordana MT. Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci. 2014;35:523–30.CrossRefPubMed Maffeo E, Montuschi A, Stura G, Giordana MT. Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci. 2014;35:523–30.CrossRefPubMed
55.
go back to reference Miletić V, Ozretić D, Relja M. Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration. Metab Brain Dis. 2014;29:207–9.CrossRefPubMed Miletić V, Ozretić D, Relja M. Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration. Metab Brain Dis. 2014;29:207–9.CrossRefPubMed
56.
go back to reference Criswell SR, Perlmutter JS, Crippin JS, Tom O, Racette BA. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Arch Neurol. 2012;69:394–7.CrossRefPubMedPubMedCentral Criswell SR, Perlmutter JS, Crippin JS, Tom O, Racette BA. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Arch Neurol. 2012;69:394–7.CrossRefPubMedPubMedCentral
57.
go back to reference Ishii K, Shioya A, Fukuda K, Mori K, Tamaoka A. Acquired hepatocerebral degeneration with middle cerebellar peduncles lesions: case report and review of the literature. Clin Neurol Neurosurg. 2012;114:1361–4.CrossRefPubMed Ishii K, Shioya A, Fukuda K, Mori K, Tamaoka A. Acquired hepatocerebral degeneration with middle cerebellar peduncles lesions: case report and review of the literature. Clin Neurol Neurosurg. 2012;114:1361–4.CrossRefPubMed
58.
go back to reference Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008;23:768–70.CrossRefPubMed Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008;23:768–70.CrossRefPubMed
59.
go back to reference Ueki Y, Isozaki E, Miyazaki Y, Koide R, Shimizu T, et al. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy. Acta Neurol Scand. 2002;106:113–6.CrossRefPubMed Ueki Y, Isozaki E, Miyazaki Y, Koide R, Shimizu T, et al. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy. Acta Neurol Scand. 2002;106:113–6.CrossRefPubMed
60.
go back to reference Lazeyras F, Spahr L, DuPasquier R, Delavelle J, Burkhard P, et al. Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transpl Int. 2002;15:188–95.CrossRefPubMed Lazeyras F, Spahr L, DuPasquier R, Delavelle J, Burkhard P, et al. Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transpl Int. 2002;15:188–95.CrossRefPubMed
61.
go back to reference Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol. 2006;11(2):117–25. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol. 2006;11(2):117–25.
62.•
go back to reference Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417–32. Review of pharmacokinetic aspects and safety issues for the use of antiepileptic drugs in patients with hepatic disease.CrossRefPubMed Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417–32. Review of pharmacokinetic aspects and safety issues for the use of antiepileptic drugs in patients with hepatic disease.CrossRefPubMed
63.
go back to reference Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410–7.CrossRefPubMedPubMedCentral Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410–7.CrossRefPubMedPubMedCentral
64.
go back to reference Hsu C-S, Kao J-H, Chao Y-C, Lin HH, Fan Y-C, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415–23.CrossRefPubMed Hsu C-S, Kao J-H, Chao Y-C, Lin HH, Fan Y-C, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415–23.CrossRefPubMed
65.
go back to reference Yan P, Zhu A, Liao F, Xiao Q, Kraft AW, et al. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke. 2015;46:1633–40.CrossRefPubMedPubMedCentral Yan P, Zhu A, Liao F, Xiao Q, Kraft AW, et al. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke. 2015;46:1633–40.CrossRefPubMedPubMedCentral
66.
go back to reference Mehndiratta M, Pandey S, Nayak R, Saran RK. Acute onset distal symmetrical vasculitic polyneuropathy associated with acute hepatitis B. J Clin Neurosci. 2013;20:331–2.CrossRefPubMed Mehndiratta M, Pandey S, Nayak R, Saran RK. Acute onset distal symmetrical vasculitic polyneuropathy associated with acute hepatitis B. J Clin Neurosci. 2013;20:331–2.CrossRefPubMed
68.
go back to reference Cheung MCM, Maguire J, Carey I, Wendon J, Agarwal K. Review of the neurological manifestations of hepatitis E infection. Ann Hepatol. 2012;11:618–22.PubMed Cheung MCM, Maguire J, Carey I, Wendon J, Agarwal K. Review of the neurological manifestations of hepatitis E infection. Ann Hepatol. 2012;11:618–22.PubMed
69.
go back to reference El Moutawakil B, Bourezgui M, Rafai MA, Sibai M, Boulaajaj FZ, et al. Acute disseminated encephalomyelitis associated with hepatitis A virus infection. Rev Neurol (Paris). 2008;164:852–4.CrossRef El Moutawakil B, Bourezgui M, Rafai MA, Sibai M, Boulaajaj FZ, et al. Acute disseminated encephalomyelitis associated with hepatitis A virus infection. Rev Neurol (Paris). 2008;164:852–4.CrossRef
70.
go back to reference Sellner J, Steiner I. Neurologic complications of hepatic viruses. Handb Clin Neurol. 2014;123:647–61.CrossRefPubMed Sellner J, Steiner I. Neurologic complications of hepatic viruses. Handb Clin Neurol. 2014;123:647–61.CrossRefPubMed
71.
go back to reference Mengel AM, Stenzel W, Meisel A, Büning C. Hepatitis E induced severe myositis. Muscle Nerve. Published Online First: 29 October 2015. Mengel AM, Stenzel W, Meisel A, Büning C. Hepatitis E induced severe myositis. Muscle Nerve. Published Online First: 29 October 2015.
72.
go back to reference Perrin HB, Cintas P, Abravanel F, Gérolami R, d’Alteroche L, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21(11):1928–34. Perrin HB, Cintas P, Abravanel F, Gérolami R, d’Alteroche L, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21(11):1928–34.
73.
go back to reference Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. 2015. Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. 2015.
74.
go back to reference Yazaki Y, Sugawara K, Honda M, Ohnishi H, Nagashima S, et al. Characteristics of 20 patients with autochthonous acute hepatitis E in Hokkaido, Japan: first report of bilateral facial palsy following the infection with genotype 4 hepatitis E virus. Tohoku J Exp Med. 2015;236:263–71.CrossRefPubMed Yazaki Y, Sugawara K, Honda M, Ohnishi H, Nagashima S, et al. Characteristics of 20 patients with autochthonous acute hepatitis E in Hokkaido, Japan: first report of bilateral facial palsy following the infection with genotype 4 hepatitis E virus. Tohoku J Exp Med. 2015;236:263–71.CrossRefPubMed
75.
go back to reference Deroux A, Brion JP, Hyerle L, Belbezier A, Vaillant M, et al. Association between hepatitis E and neurological disorders: two case studies and literature review. J Clin Virol. 2014;60:60–2.CrossRefPubMed Deroux A, Brion JP, Hyerle L, Belbezier A, Vaillant M, et al. Association between hepatitis E and neurological disorders: two case studies and literature review. J Clin Virol. 2014;60:60–2.CrossRefPubMed
76.
go back to reference Domingos JP, Garrido C, Moreira Silva H, Monteiro C, Silva ES, et al. Chronic inflammatory demyelinating polyneuropathy associated with autoimmune hepatitis. Pediatr Neurol. 2014;51:e13–4.CrossRefPubMed Domingos JP, Garrido C, Moreira Silva H, Monteiro C, Silva ES, et al. Chronic inflammatory demyelinating polyneuropathy associated with autoimmune hepatitis. Pediatr Neurol. 2014;51:e13–4.CrossRefPubMed
77.
go back to reference Park KH, Sohn SY, Sung JJ, Lee KW, Hong YH. Subacute sensorimotor polyneuropathy associated with autoimmune hepatitis. J Clin Neurol. 2016;12(1):123–5. Park KH, Sohn SY, Sung JJ, Lee KW, Hong YH. Subacute sensorimotor polyneuropathy associated with autoimmune hepatitis. J Clin Neurol. 2016;12(1):123–5.
78.
go back to reference Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950–5.CrossRefPubMed Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950–5.CrossRefPubMed
79.•
go back to reference Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis. 2014;73:24–30. Review of treatment options for hepatitis C virus-induced vasculitis.CrossRefPubMed Cacoub P, Terrier B, Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis. 2014;73:24–30. Review of treatment options for hepatitis C virus-induced vasculitis.CrossRefPubMed
80.
go back to reference Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835–42.CrossRefPubMedPubMedCentral Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835–42.CrossRefPubMedPubMedCentral
81.
go back to reference De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.CrossRefPubMed De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.CrossRefPubMed
82.
go back to reference Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014;12:CD010404.PubMed Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014;12:CD010404.PubMed
83.•
go back to reference Ahrens CL, Manno EM. Neurotoxicity of commonly used hepatic drugs. Handb Clin Neurol. 2014;120:675–82. Overview of neurologic complications related to commonly used hepatic drugs.CrossRefPubMed Ahrens CL, Manno EM. Neurotoxicity of commonly used hepatic drugs. Handb Clin Neurol. 2014;120:675–82. Overview of neurologic complications related to commonly used hepatic drugs.CrossRefPubMed
84.
go back to reference Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMed Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMed
85.
go back to reference Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMed Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMed
86.
go back to reference Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed
87.
go back to reference Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMed Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMed
Metadata
Title
Management of Neurologic Manifestations in Patients with Liver Disease
Authors
José M. Ferro, MD, PhD
Pedro Viana, MD
Patrícia Santos, MD
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 8/2016
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-016-0419-0